ORIGINAL RESEARCH article
Front. Med.
Sec. Rheumatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1538170
Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: Comparison of patients over and under 75 years old
Provisionally accepted
- 1Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
- 2UMRS 1136, Paris, France
- 3INSERM U1227 Lymphocytes B et Autoimmunite (LBAI), Brest, Brittany, France
- 4Hôpital de la Cavale Blanche, CHRU Brest, Brest, Brittany, France
- 5Chugai Pharma France, Paris La Défense, France
- 6Université de Montpellier, Montpellier, Languedoc-Roussillon, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Rheumatoid arthritis (RA) is an increasingly important health concern among elderly people who are particularly affected by the disease. Considering the growing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) in RA, it is then crucial to know how such treatments can be used effectively and safely in this comorbid and frail population. Since elderly are usually excluded from clinical trials, few information is available on the use of bDMARDs in this specific population. In this context, our real-world study aimed to compare the long-term management with tocilizumab (TCZ), an IL-6R inhibitor, in RA patients over and under 75 years of age. Our findings are based on patient data extracted from a national public database (the French National administrative Healthcare database, SNDS) covering 99% of the population living in France. Such comprehensive data, with a follow-up duration of 3 to 5 years after the first TCZ delivery, allowed us to provide new and informative results in representative patient groups according to their age. On these bases, we think that Frontiers in Medicine-Rheumatology is a particularly suitable journal in which to publish our results which we believe represent original and clinically important findings of interest.
Keywords: Conceptualization, methodology, supervision, Validation, Writing -review & editing. Bernard Combe: Conceptualization, Writing -review & editing. Bruno Fautrel: Conceptualization, Writing -review & editing. Isabelle Idier: Conceptualization, Writing -original draft Rheumatoid arthritis
Received: 02 Dec 2024; Accepted: 29 Jul 2025.
Copyright: © 2025 Fautrel, Saraux, Idier and Combe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bruno Fautrel, Hôpitaux Universitaires Pitié Salpêtrière, Paris, 75651, France
Isabelle Idier, Chugai Pharma France, Paris La Défense, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.